Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.
Courtney D Di NardoAnthony S SteinEytan M SteinAmir T FathiOlga FrankfurtAndre C SchuhHartmut DöhnerGiovanni MartinelliPrapti A PatelEmmanuel RaffouxPeter TanAmer M ZeidanStéphane de BottonHagop M KantarjianRichard M StoneMark G FrattiniFrederik LerschJing GongDiego A GianolioVickie ZhangAleksandra FranovicBin FanMeredith GoldwasserScott DaigleSung ChoeBin WuThomas WinklerParesh VyasPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
Ivosidenib plus azacitidine was well tolerated, with an expected safety profile consistent with monotherapy with each agent. Responses were deep and durable, with most complete responders achieving mIDH1 mutation clearance.